Literature DB >> 28704108

Reliability of kinetic visual field testing in children with mutation-proven retinal dystrophies: Implications for therapeutic clinical trials.

Vaidehi S Dedania1, Jerry Y Liu1, Dana Schlegel1, Chris A Andrews1, Kari Branham1, Naheed W Khan1, David C Musch1,2, John R Heckenlively1, K Thiran Jayasundera1.   

Abstract

PURPOSE: Kinetic visual field testing is used to monitor disease course in retinal dystrophy clinical care and treatment response in treatment trials, which are increasingly recruiting children. This study investigates Goldmann visual field (GVF) changes in young children with mutation-proven retinal dystrophies as they age and with progression of the retinal degeneration.
METHODS: Retrospective review of children ≤ 17 years old with a mutation-proven retinal dystrophy. Objective clinical disease activity was assessed by a retinal degeneration specialist masked to GVF results. Digital quantification of GVF area was performed.
RESULTS: Twenty-nine children (58 eyes), ages 5-16, were identified. GVF area increased with age despite progression in 20 children and clinical stability in nine children. Mean ± standard error increase in GVF area/year was 333 ± 130 mm2 (I4e, p = 0.012), 720 ± 155 mm2 (III4e, p < 0.001), and 759 ± 167 mm2 (IV4e, p < 0.001), with greater increases at earlier ages. Repeatability coefficients were 7381 mm2 (I4e), 9379 mm2 (III4e), and 10346 mm2 (IV4e), indicating a large variability. At 2.5 years after the baseline GVF the area increased ≥ 20%, the criterion for positive treatment outcome defined in recent published therapeutic trials, in 38% (I4e), 34% (III4e), and 33% (IV4e) of eyes.
CONCLUSION: In a substantial proportion of children with mutation-proven retinal dystrophies, there is a significant increase in GVF area with age, particularly those < 12 years, despite progression or stability of disease. These findings suggest that change in GVF area in children with retinal dystrophies can be an unreliable measure of response to treatment and on which to base appropriate counseling about visual impairment.

Entities:  

Keywords:  Children; Goldmann visual field; kinetic visual field; retinal degeneration; retinal dystrophy; visual field testing

Mesh:

Year:  2017        PMID: 28704108      PMCID: PMC5938742          DOI: 10.1080/13816810.2017.1329447

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  19 in total

1.  Effect of instructions on conventional automated perimetry.

Authors:  K E Kutzko; C F Brito; M Wall
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-06       Impact factor: 4.799

2.  The role of verbal behavior in human learning: III. Instructional effects in children.

Authors:  R P Bentall; C F Lowe
Journal:  J Exp Anal Behav       Date:  1987-03       Impact factor: 2.468

3.  Automated visual field examination in children aged 5-8 years. Part I: Experimental validation of a testing procedure.

Authors:  C Tschopp; A B Safran; P Viviani; A Bullinger; M Reicherts; C Mermoud
Journal:  Vision Res       Date:  1998-07       Impact factor: 1.886

4.  Peripheral vision in children and adults.

Authors:  J A Whiteside
Journal:  Child Dev       Date:  1976-03

5.  Growth pattern of the eye from birth to maturity: an Indian study.

Authors:  Ruma Purkait
Journal:  Aesthetic Plast Surg       Date:  2013-01-11       Impact factor: 2.326

6.  A new era in medical therapy for retinal degenerative disease?

Authors:  Alessandro Iannaccone; Marco A Zarbin
Journal:  Lancet       Date:  2014-07-13       Impact factor: 79.321

7.  Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa.

Authors:  William Seiple; Colleen J Clemens; Vivienne C Greenstein; Ronald E Carr; Karen Holopigian
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

8.  The development of sustained attention (vigilance) and inhibition in children: some normative data.

Authors:  F Levy
Journal:  J Child Psychol Psychiatry       Date:  1980-01       Impact factor: 8.982

9.  Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.

Authors:  Robert K Koenekoop; Ruifang Sui; Juliana Sallum; L Ingeborgh van den Born; Radwan Ajlan; Ayesha Khan; Anneke I den Hollander; Frans P M Cremers; Janine D Mendola; Ava K Bittner; Gislin Dagnelie; Ronald A Schuchard; David A Saperstein
Journal:  Lancet       Date:  2014-07-13       Impact factor: 79.321

10.  Normative values for visual fields in 4- to 12-year-old children using kinetic perimetry.

Authors:  M Wilson; G Quinn; V Dobson; M Breton
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1991 May-Jun       Impact factor: 1.402

View more
  5 in total

1.  Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.

Authors:  Callie Deng; Peter Y Zhao; Kari Branham; Dana Schlegel; Abigail T Fahim; Thiran K Jayasundera; Naheed Khan; Cagri G Besirli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-10       Impact factor: 3.535

2.  Clinical trial design for neuroprotection in RHO autosomal dominant retinitis pigmentosa; outcome measure considerations.

Authors:  Benjamin Otte; Chris Andrews; Gabrielle Lacy; Kari Branham; David C Musch; Kanishka T Jayasundera
Journal:  Ophthalmic Genet       Date:  2021-01-06       Impact factor: 1.803

3.  Calculation of test-retest variability in phase I/IIa clinical trials for Inherited Retinal Degenerations.

Authors:  Jacob Jeries Abou-Hanna; Chris A Andrews; Naheed W Khan; David C Musch; K Thiran Jayasundera
Journal:  Ophthalmic Genet       Date:  2021-03-17       Impact factor: 1.274

4.  Genotypes and phenotypes of genes associated with achromatopsia: A reference for clinical genetic testing.

Authors:  Wenmin Sun; Shiqiang Li; Xueshan Xiao; Panfeng Wang; Qingjiong Zhang
Journal:  Mol Vis       Date:  2020-08-22       Impact factor: 2.367

5.  PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.

Authors:  Malena Daich Varela; Ehsan Ullah; Sairah Yousaf; Brian P Brooks; Robert B Hufnagel; Laryssa A Huryn
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.